Urologists, radiologists and pathologists from Europe and the US agreed an “expert consensus statement” on prostate cancer treatment and diagnosis ...
It’s important to follow guidance on prostate-specific antigen screening that maximizes benefits and minimizes potential harms such as overdiagnosis and overtreatment.
A meta-analysis seeks to determine if adding hormone therapy to radiotherapy after prostatectomy improves overall survival.
New data show bimekizumab is the first approved biologic to achieve superior outcomes in psoriatic arthritis vs an IL-23 inhibitor.
A single PSA test at midlife may identify men with a low risk of prostate cancer for up to 20 years, supporting longer screening intervals. Men with a low baseline PSA level at midlife have a low risk ...
PSA's February 2026 Price Hike Details PSA implemented these psa grading price increases in February 2026 to match surging demand with operational capacity, ensuring more reliable service delivery.
We came across a bullish thesis on Public Storage on R. Dennis’s Substack by OppCost. In this article, we will summarize the bulls’ thesis on PSA. Public Storage’s share was trading at $304.11 as of ...
Study found men with low testosterone levels were associated with a 60% higher likelihood that prostate cancer managed on active surveillance would progress to a more aggressive state over time ...
13don MSN
Hormone therapy may not benefit most men receiving radiotherapy after prostate surgery, study finds
A new study led by UCLA Health Jonsson Comprehensive Cancer Center investigators suggests that adding hormone therapy to postoperative radiotherapy may provide little survival benefit for most men ...
The introduction of the Premium Annotation Service at CRS outlets, according to Catubuan, reflects the continuing commitment of the PSA to bring efficient, responsive, and high-quality civil ...
THE Philippines remains above its 2030 target for reducing maternal deaths, despite steady improvements over the past five years. Data from the 2024 Civil Registration and Vital Statistics (CRVS) ...
FDA approves Pylarify TruVu, a new prostate cancer PET imaging agent designed to expand access and improve detection of recurrent or metastatic disease.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results